

**Out. number: 194-00-71/25.10.2024**

**Notification on the terms and conditions for distribution of the dividend voted at the Extraordinary General Meeting of Shareholders of "Sopharma" AD held on October 25, 2024**

**Sofia, Bulgaria**, October 25, 2024 – In accordance with the requirements of art. 115c, para. 4 of LPOS "**Sopharma**" AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies all shareholders of the Company about the decision of the EGM of "Sopharma" AD that took place on October 25, 2024 regarding the 6-month dividend for 2024 and the terms and conditions for its distribution:

The EGM approves the proposal by the Board of Directors for the distribution of gross 6-month dividend at the amount of BGN 0.075 /seven and a half stotinki/ per share.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the EGM on which the 6-month Financial Report was approved and the decision for the distribution of a 6-month dividend was taken, namely November 8, 2024 (dividend record date) – ex-dividend date November 7, 2024. The starting date for dividend payment is December 23, 2024.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary – through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of "Eurobank EFG – Bulgaria" AD /Postbank/ in the country.

All foreign shareholders who wish to provide original documents to avoid double taxation, please do so no later than December 6, 2024 at the following address: Sofia 1756, 5, Lachezar Stanchev St., Tower A, fl. 11 at the attention of the Investor Relations Director (contacts for additional information [ir@sopharma.bg](mailto:ir@sopharma.bg) / +359 2 8134 319).

Pelagia Viatcheva

Investor Relations Director

**Information about the company**

**"Sopharma" AD**

*90 years of tradition and modernity - European GMP standards and quality, leader in market cap on the Bulgarian Stock Exchange, good corporate governance practices compliant.*

*Sopharma produces active pharmaceutical ingredients and medicinal products; conducts activities related to research, development and implementation in the field of phytochemistry, chemistry and pharmaceuticals, provides services related to production and auxiliary activities.*

*With 9 pharmaceutical plants in the country, including a unique ampoule factory in Bulgaria, the company produces more than 4 billion tablets, 9 million syrup forms, has marketing authorization for over 200 generic products, 15 traditional products, including 12 plant-based for which it uses more than 1500 tons of medicinal plants.*

*Sopharma has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma consistently invests in new technologies, innovations, research and sustainability. The company maintains a dialogue with all interested parties in the pharmaceutical industry and strives to contribute to improving the healthcare sector.*

**Sopharma Group**

*Sopharma Group is a vertically integrated health related business, that operates in important sectors such as medicinal products' manufacturing, hospital supplies, medicinal products' distribution, retail and many others.*